Wuhan YZY Biopharmaceutical Co., Ltd. has developed a bispecific antibody (PD-L1 x CD3) Y111 that targets PD-L1 and CD3, effectively facilitating the interaction between T cells and tumor cells expressing PD-L1. Here, CD274 is linked to neoplasm.